American Heart Journal
Volume 154, Issue 3 , Pages 561-566 , September 2007

Connexin37 (GJA4) genotype predicts survival after an acute coronary syndrome

  • David E. Lanfear, MD, MS

      Affiliations

    • Henry Ford Heart and Vascular Institute and Wayne State University, Detroit, MI
    • ,
  • Philip G. Jones, MS

      Affiliations

    • Mid America Heart Institute, Kansas City, MO
    • ,
  • Sharon Marsh, PhD

      Affiliations

    • Department of Medicine, Washington University School of Medicine, St Louis, MO
    • ,
  • Sharon Cresci, MD

      Affiliations

    • Cardiovascular Diseases Division, Department of Medicine, Washington University School of Medicine, St Louis, MO
    • ,
  • John A. Spertus, MD, MPH

      Affiliations

    • Mid America Heart Institute, Kansas City, MO
    • University of Missouri-Kansas City, Kansas City, MO
    • Corresponding Author InformationReprint requests: John Spertus, MD, MPH, Mid America Heart Institute, 4401 Wornall Road, Kansas City, MO 64111.
    • ,
  • Howard L. McLeod, PharmD

      Affiliations

    • Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill, NC

Received 1 December 2006 ,Accepted 29 April 2007.

References 

  1. Rathz DA, Gregory KN, Fang Y, et al. Hierarchy of polymorphic variation and desensitization permutations relative to beta 1- and beta 2-adrenergic receptor signaling. J Biol Chem. 2003;278:10784–10789
  2. Yamada Y, Izawa H, Ichihara S, et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med. 2002;347:1916–1923
  3. Hirashiki A, Yamada Y, Murase Y, et al. Association of gene polymorphisms with coronary artery disease in low- or high-risk subjects defined by conventional risk factors. J Am Coll Cardiol. 2003;42:1429–1437
  4. Wong CW, Christen T, Roth I, et al. Connexin37 protects against atherosclerosis by regulating monocyte adhesion. Nat Med. 2006;12:950–954
  5. Lanfear DE, Marsh S, Cresci S, et al. Genotypes associated with myocardial infarction risk are more common in African Americans than in European Americans. J Am Coll Cardiol. 2004;44:165–167
  6. Lanfear DE, Jones PG, Marsh S, et al. Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. JAMA. 2005;294:1526–1533
  7. Marsh S, King CR, Garsa AA, et al. Pyrosequencing of clinically relevant polymorphisms. Methods Mol Biol. 2005;311:97–114
  8. Listi F, Candore G, Lio D, et al. Association between C1019T polymorphism of connexin37 and acute myocardial infarction: a study in patients from Sicily. Int J Cardiol. 2005;102:269–271
  9. Boerma M, Forsberg L, Van Zeijl L, et al. A genetic polymorphism in connexin 37 as a prognostic marker for atherosclerotic plaque development. J Intern Med. 1999;246:211–218
  10. Yeh HI, Chou Y, Liu HF, et al. Connexin37 gene polymorphism and coronary artery disease in Taiwan. Int J Cardiol. 2001;81:251–255
  11. Yamada Y, Ichihara S, Izawa H, et al. Genetic risk for coronary artery disease in individuals with or without type 2 diabetes. Mol Genet Metab. 2004;81:282–290

 This work was supported in part by R01 HS11282-01 from the Agency for Healthcare Research and Quality, the NIH Pharmacogenetics research network (U01 GM63340), a Heart Failure Society of America Research Fellowship grant, and NIH SCCOR (P50 HL077113).

 Dr Howard L. McLeod is a member of an advisory board for the US Food and Drug Administration.

PII: S0002-8703(07)00384-5

doi: 10.1016/j.ahj.2007.04.059

American Heart Journal
Volume 154, Issue 3 , Pages 561-566 , September 2007

Article Tools

* Image Usage & Resolution